Literature DB >> 11923641

Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity.

F Kiessling1, C Fink, M Hansen, M Bock, H Sinn, H H Schrenk, M Krix, T Egelhof, N E Fusenig, S Delorme.   

Abstract

RATIONALE: Malignant tumors often show an increased uptake and metabolism of plasma proteins, especially albumin.
OBJECTIVES: Determine whether the accumulation of low loaded Gd-albumin improves visualization of malignant tumors by MRI.
METHODS: Twelve nude mice with heterotransplanted squamous cell carcinomas were studied. The signal intensity of tumor, blood, liver, kidney and muscle tissue was studied in MR images after application of Gd-albumin during a period of 144 hours. MRI results were histologically correlated after simultaneously injection of Gd- and fluorescein-labeled albumins in 9 nude mice.
RESULTS: Although liver and kidney had a maximum increase in signal intensity within 30 minutes, tumors showed a delayed 51% increase in the 24 hours after application. Histologic and fluorescence evaluation demonstrated albumin localization in tumors predominantly in stroma and necroses.
CONCLUSIONS: Gd-albumin is efficiently accumulated in SCC transplants. MRI with low loaded Gd-albumin may offer relevant opportunities for recognizing tumors sensitive to a therapy with cyostic drug-labeled albumins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923641     DOI: 10.1097/00004424-200204000-00004

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  7 in total

1.  Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI.

Authors:  Kido Nwe; Diane Milenic; L Henry Bryant; Celeste A S Regino; Martin W Brechbiel
Journal:  J Inorg Biochem       Date:  2011-04-02       Impact factor: 4.155

2.  Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.

Authors:  Fabian Kiessling; Nabeel Farhan; Matthias P Lichy; Silvia Vosseler; Melanie Heilmann; Martin Krix; Peter Bohlen; Dan W Miller; Margareta M Mueller; Wolfhard Semmler; Norbert E Fusenig; Stefan Delorme
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

Review 3.  Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?

Authors:  Chen Liang; Si Shi; Qingcai Meng; Dingkong Liang; Shunrong Ji; Bo Zhang; Yi Qin; Jin Xu; Quanxing Ni; Xianjun Yu
Journal:  Cell Mol Life Sci       Date:  2017-10-09       Impact factor: 9.261

4.  SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.

Authors:  Harrison Kim; Sharon Samuel; Pedro Lopez-Casas; William Grizzle; Manuel Hidalgo; Joy Kovar; Denise Oelschlager; Kurt Zinn; Jason Warram; Donald Buchsbaum
Journal:  Mol Cancer Ther       Date:  2016-02-01       Impact factor: 6.261

5.  Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Authors:  Anne Steins; Eva A Ebbing; Marcel C M Pistorius; Cynthia Waasdorp; Kausilia K Krishnadath; Jan Paul Medema; Johanna W Wilmink; Ron A A Mathôt; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 6.  Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs.

Authors:  Rodrigo Dos A Miguel; Amanda S Hirata; Paula C Jimenez; Luciana B Lopes; Leticia V Costa-Lotufo
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

7.  SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer.

Authors:  Kazutoshi Komiya; Tomomi Nakamura; Chiho Nakashima; Koichiro Takahashi; Hitomi Umeguchi; Naomi Watanabe; Akemi Sato; Yuji Takeda; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  Onco Targets Ther       Date:  2016-10-27       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.